BioSpace News Archive

BioForest

Poll Takers Place Opioid Crisis Blame at the Feet of the Pharmaceutical Industry

A new poll shows nearly two-thirds of people blame the pharmaceutical companies for the opioid crisis.

April 26, 2019
·
3 min read
·
Alex Keown
FDA

From the Ashes of Scandal, Bausch Health Moves Ahead With Psoriasis Approval

Bausch Health, former known as Valeant Pharmaceuticals International, announced that the U.S. Food and Drug Administration (FDA) had approved its Duobrii (halobetasol propionate and tazoretene) Lotion for plaque psoriasis.

April 26, 2019
·
3 min read
·
Mark Terry
Drug Development

Merck’s Keytruda Has Mixed Results in Phase III Gastric Cancer Study

As a monotherapy, Keytruda showed non-inferiority to standard of care but missed the mark as a combination treatment.

April 26, 2019
·
3 min read
·
Alex Keown
FDA

FDA Action Alert: Regeneron and Sanofi have a Busy Week, Plus Heron and Nabriva

This week has a number of approvals expected by the U.S. Food and Drug Administration. Let’s take a look.

April 26, 2019
·
4 min read
·
Mark Terry
Business

Expedeon Reports Financial Results for Fiscal Year 2018 – Financial Guidance Met

Conference call to be held today, 25 April 2019, 3:00pm CET/2:00pm BST

April 26, 2019
·
8 min read
Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019

At the Annual General Meeting of Immunicum AB (publ), reg. no 556629-1786, on April 25, 2019 the AGM adopted, inter alia, the following resolutions.

April 26, 2019
·
5 min read
Business

DCprime Strengthens Supervisory Board with the Additions of Andrea van Elsas and Hans Preusting

DCprime announced the appointment of two highly-experienced industry veterans, Andrea van Elsas, Ph.D. and Hans Preusting, Ph.D., M.B.A, to its Supervisory Board.

April 26, 2019
·
2 min read
Business

Galapagos reports on historic first quarter 2019

Galapagos NV presents financial results and highlights the key events for the first quarter of 2019.

April 26, 2019
·
7 min read
Deals

Roche’s Spark Buyout Delayed … Again

This is the second extension that has been filed, this time delaying it until June 3. The companies indicate it is because U.S. authorities are taking longer than expected to review the deal.

April 26, 2019
·
2 min read
·
Mark Terry
Business

Immunicum AB (publ) Interim Report January - March 2019

Preparations for Upcoming Clinical Data in the MERECA and GIST Studies and First Patient Treated in the ILIAD Study

April 26, 2019
·
4 min read